Search AI Products and News

As a generative AI social startup, CHAI has achieved threefold growth annually over the past three years, with an ARR of $68 million and a valuation exceeding $1.4 billion. While rapidly expanding its user base, the company has upgraded its safety framework, focusing on strengthening suicide prevention and self-harm intervention measures, emphasizing AI safety responsibility.

Research reveals a critical flaw in autonomous vehicles: attackers can exploit visual language model vulnerabilities by printing specific text on signs, misleading vehicles into dangerous actions, such as driving toward pedestrians, highlighting risks of over-reliance on visual cues.....

Chai Discovery partners with Eli Lilly, using its AI algorithm Chai-2 to accelerate antibody drug development. Founded by OpenAI alumni with CEO backing, it highlights AI's potential in biopharma.....

AI drug development company Chai Discovery completes $130 million Series B funding, with a post-funding valuation of $1.3 billion, becoming a unicorn company. The round was led by General Catalyst and Oak HC/FT, with existing shareholders continuing to invest and new investors joining.

Chai Discovery completes $130 million in Series B funding, with a valuation of $1.3 billion, led by General Catalyst and Oak HC/FT, with participation from several renowned investment institutions. The company's total funding exceeds $225 million, focusing on drug discovery. The industry is gradually recognizing the potential of artificial intelligence in drug development.

Chai Discovery secures $130M in Series B funding at a $1.3B valuation, led by General Catalyst and Oak HC/FT, with participation from Menlo Ventures and OpenAI, strengthening its leadership in AI-driven drug discovery.....

Artificial intelligence once again stirs up the field of drug development! Chai Discovery recently launched a new AI model called Chai-2, which has drawn widespread attention with its breakthrough technology in molecular design. Chai-2 achieves zero-shot antibody design with a success rate of 16%-20%, hundreds of times higher than traditional methods, shortening the drug development cycle from months or even years to just two weeks. Zero-shot antibody design breaks through traditional bottlenecks. Chai-2 is a multi-modal generative AI model developed by Chai Discovery, specifically designed for...

Biotech startup Chai Discovery has launched the AI model Chai-1, aimed at predicting molecular structures to aid drug development. This model surpasses Google's DeepMind AlphaFold in accuracy and has been supported by OpenAI and Thrive Capital. Chai-1's free web interface and open-source code encourage non-commercial research. The model excels in predicting various types of molecules, particularly demonstrating unexpected accuracy when data is incomplete, contributing significantly to drug development.